Sécurité et efficacité à long terme de l'Ixekizumab chez les patients atteints de spondylarthrite axiale : Données à 3 ans du programme COAST
J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022
Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.